Table 1.
Participant description
| Patients with a baseline visit, N = 63 (%) | Patients with complete VAS data for both visits, N = 47 (%) | Patients with complete HRV data for both visits, N = 34 (%) | |
|---|---|---|---|
| Age | |||
| Mean ± standard deviation (yrs) | 9 ± 5.3 | 10.4 ± 5.1 | 9.5 ± 4.9 |
| Median (yrs) | 8 | 10.7 | 9.4 |
| Range (yrs) | 0.8, 17.9 | 0.8, 17.9 | 0.8, 17.6 |
| Gender—% male | 40 (63) | 28 (60) | 18 (53) |
| Race | |||
| African American | 12 (19) | 11 (23) | 8 (24) |
| White | 47 (75) | 34 (72) | 24 (71) |
| Mixed/other | 4 (6) | 2 (4) | 2 (6) |
| Ethnicity—Hispanic | 4 (6) | 2 (4) | 1 (3) |
| Diagnosis | |||
| ALL | 50 (79) | 36 (77) | 26 (76) |
| Other | 11 (21) | 11 (23) | 8 (24) |
| Comorbidities (some patients had none, while others had more than one)—any | 24 (38) | 19 (40) | 14 (41) |
| Asthma/allergies | 9 (14) | 7 (15) | 4 (12) |
| Congenital/genetic | 6 (11) | 4 (10) | 2 (7) |
| Hypertension | 3 (5) | 3 (6) | 3 (9) |
| Stage of treatment | |||
| Continuation | 24 (38) | 16 (34) | 15 (44) |
| Consolidation | 31 (49) | 25 (53) | 15 (44) |
| Other | 8 (13) | 6 (13) | 4 (12) |
| Ever treated with doxorubicin | 38 (61) | 33 (70) | 26 (77) |
ALL indicates acute lymphoblastic leukemia; HRV, heart rate variability; VAS, visual analog scale.